Close Menu

NEW YORK (GenomeWeb) – Amarantus BioScience Holdings today said that it closed on a $5 million investment from privately held mutual fund Discover Growth Fund. 

Amarantus plans to use the financing to further develop and commercialize its neurology diagnostic products and therapeutic drug candidates, and for other working capital expenses, it said. In conjunction with the investment, the San Francisco-based company issued a new class of preferred stock, Series G, that is convertible into Amarantus' common stock at a fixed price of $.06 per share. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.

Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.

Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.

In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.

Sep
16
Sponsored by
ArcherDX

This webinar will discuss a next-generation sequencing approach for detecting genomic mutations in hematologic maglignancies.

Sep
18
Sponsored by
Bionano Genomics

This webinar will outline how a team at Radboud University Medical Center is assessing ultra-long read optical mapping on the Bionano Saphyr system to replace classical cytogenetics approaches in routine testing and for the discovery of novel structural variants with potential scientific, prognostic, or therapeutic value that are missed by standard approaches.

Sep
25
Sponsored by
HalioDx

CAR T-cell therapy is an innovative form of immunotherapy that is finding increasing use for the management of blood cancers. 

Oct
02
Sponsored by
10x Genomics

This webinar will discuss a study that used spatial transcriptomics to gain insight into the molecular mechanisms of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease.